![Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2018/edbk.2018.38/edbk_200967/20180622/images/large/edbk_200967_table2.jpeg)
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book
![ASCO 2020: Molecular Determinants of PSA Kinetics and Clinical Response to Apalutamide in Patients with nmCRPC in SPARTAN ASCO 2020: Molecular Determinants of PSA Kinetics and Clinical Response to Apalutamide in Patients with nmCRPC in SPARTAN](https://www.urotoday.com/images/ASCO_2020_SPARTAN_1.png)
ASCO 2020: Molecular Determinants of PSA Kinetics and Clinical Response to Apalutamide in Patients with nmCRPC in SPARTAN
![SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer - Onco Americas SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer - Onco Americas](https://www.oncoamericas.com/wp-content/uploads/2020/10/ingles-2.1.png)
SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer - Onco Americas
ESMO 2019: Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study
![ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer](https://www.urotoday.com/images/ASCO20_SPARTAN2.png)
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
![Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract](https://www.urotoday.com/images/GS2669_SPARTAN_FA_Commentary_Figure_1.jpg)
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
![Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial - The Lancet Oncology Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/45f4c971-f070-4e0b-a630-afda3bf04a09/gr1_lrg.jpg)
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
![ASCO GU 2022: Association between PROs and Changes in PSA in Patients with Advanced Prostate Cancer Treated with Apalutamide in the SPARTAN and TITAN Studies ASCO GU 2022: Association between PROs and Changes in PSA in Patients with Advanced Prostate Cancer Treated with Apalutamide in the SPARTAN and TITAN Studies](https://www.urotoday.com/images/SPARTAN_ASCO_GU.png)
ASCO GU 2022: Association between PROs and Changes in PSA in Patients with Advanced Prostate Cancer Treated with Apalutamide in the SPARTAN and TITAN Studies
![nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/programs/strategies-in-prostate-cancer/text-module-thumbs/cco-prostate_clinical_thumb-17.png?rev=0f89ba6ad71744048f7ad8890feb0132)
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
![nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/programs/strategies-in-prostate-cancer/text-module-thumbs/cco-prostate_clinical_thumb-16.png?rev=b325a81345044df2af411f05723b80aa)
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
![An Overview of ERLEADA® (apalutamide) Efficacy, Safety and Patient-Reported Outcomes Based on the TITAN and SPARTAN Trials - Renal and Urology News An Overview of ERLEADA® (apalutamide) Efficacy, Safety and Patient-Reported Outcomes Based on the TITAN and SPARTAN Trials - Renal and Urology News](https://www.renalandurologynews.com/wp-content/uploads/sites/22/2022/05/AE-Tables-for-TITAN-and-SPARTAN.png)
An Overview of ERLEADA® (apalutamide) Efficacy, Safety and Patient-Reported Outcomes Based on the TITAN and SPARTAN Trials - Renal and Urology News
![ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer](https://www.urotoday.com/images/ESMO19_SPARTAN_trialresults_2.png)
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
![Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer | American Society of Clinical Oncology Educational Book Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2021/edbk.2021.41/edbk_321209/20210531/images/large/edbk_321209-table1.jpeg)
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer | American Society of Clinical Oncology Educational Book
![Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract](https://www.urotoday.com/images/GS2669_SPARTAN_FA_Commentary_Figure_3.jpg)